50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
S&P 500   3,719.04 (+1.97%)
DOW   29,683.74 (+1.88%)
QQQ   279.94 (+1.99%)
AAPL   149.84 (-1.27%)
MSFT   241.07 (+1.97%)
META   141.61 (+5.36%)
GOOGL   100.05 (+2.62%)
AMZN   118.01 (+3.15%)
TSLA   287.81 (+1.72%)
NVDA   127.36 (+2.60%)
NIO   17.33 (+0.81%)
BABA   80.99 (+4.01%)
AMD   68.36 (+1.77%)
T   15.83 (+0.64%)
MU   51.00 (+0.83%)
CGC   3.04 (+6.29%)
F   12.18 (+2.27%)
GE   64.46 (-0.02%)
DIS   99.40 (+3.70%)
AMC   7.67 (+2.95%)
PYPL   91.12 (+6.26%)
PFE   44.43 (+0.77%)
NFLX   245.20 (+9.29%)
NASDAQ:VTGN

VistaGen Therapeutics - VTGN News Today

$0.16
+0.01 (+6.62%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.15
$0.17
50-Day Range
$0.14
$1.07
52-Week Range
$0.14
$2.81
Volume
4.80 million shs
Average Volume
6.09 million shs
Market Capitalization
$33.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Get VistaGen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.



VTGN Media Mentions By Week

VTGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTGN
News Sentiment

0.22

0.76

Average
Medical
News Sentiment

VTGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTGN Articles
This Week

2

1

VTGN Articles
Average Week

SourceHeadline
finance.yahoo.com logoInsiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m
finance.yahoo.com - September 24 at 9:32 AM
finance.yahoo.com logoVistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
finance.yahoo.com - September 20 at 4:40 PM
finance.yahoo.com logoVistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
finance.yahoo.com - September 19 at 10:22 AM
finance.yahoo.com logoVistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
finance.yahoo.com - September 9 at 9:28 AM
finance.yahoo.com logoIndependent Biostatisticians Recommend Vistagen Continue Late-Stage Anxiety Trial
finance.yahoo.com - September 8 at 6:24 PM
finance.yahoo.com logoVistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
finance.yahoo.com - September 8 at 8:35 AM
finance.yahoo.com logoVistaGen Therapeutics, Inc. (VTGN)
finance.yahoo.com - September 6 at 10:49 PM
seekingalpha.com logoVistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss
seekingalpha.com - August 12 at 6:10 PM
seekingalpha.com logoVistaGen Therapeutics, Inc.'s (VTGN) CEO Shawn Singh on Q1 2023 Results -Earnings Call Transcript
seekingalpha.com - August 12 at 6:10 PM
finance.yahoo.com logoVistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 11 at 6:34 PM
markets.businessinsider.com logoVistaGen Therapeutics earnings preview: what to expect
markets.businessinsider.com - August 11 at 3:24 AM
nasdaq.com logoBeam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
nasdaq.com - August 9 at 10:16 AM
finance.yahoo.com logoVistaGen Therapeutics to Report Fiscal Year 2023 First Quarter Financial Results on August 11, 2022
finance.yahoo.com - August 9 at 10:16 AM
uk.investing.com logoVistagen Therapeutics Shares Are Falling Sharply: Here's Why
uk.investing.com - July 28 at 7:51 PM
benzinga.com logoVistaGen Therapeutics (NASDAQ:VTGN), Analyst Ratings, Price Targets, Predictions
benzinga.com - July 28 at 7:51 PM
benzinga.com logoThinking about buying stock in Humanigen, Versus Systems, Shopify, Vinco Ventures, or Vistagen Therapeutics?
benzinga.com - July 26 at 12:37 PM
nasdaq.com logoVistaGen : Phase 3 Trial Of PH94B In Social Anxiety Disorder Fails To Meet Primary Endpoint
nasdaq.com - July 22 at 2:29 PM
seekingalpha.com logoVistaGen drops 80% as late-stage study for anxiety therapy fails
seekingalpha.com - July 22 at 2:29 PM
finance.yahoo.com logoVistaGen Says Data From Late-Stage Anxiety Study 'Not Consistent' With Prior Positive Phase 2 Study
finance.yahoo.com - July 22 at 2:29 PM
finance.yahoo.com logoVistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
finance.yahoo.com - July 22 at 8:33 AM
morningstar.com logoVistaGen Therapeutics Inc - Stock Chart
morningstar.com - July 15 at 12:52 AM
finance.yahoo.com logoVistaGen to Participate at William Blair Biotech Focus Conference 2022
finance.yahoo.com - July 7 at 7:08 PM
seekingalpha.com logoVistaGen stock down 7% on disappointing FY result
seekingalpha.com - June 24 at 6:09 PM
seekingalpha.com logoVistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2022 Results - Earnings Call Transcript
seekingalpha.com - June 24 at 1:34 AM
finance.yahoo.com logoVistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - June 23 at 8:34 PM
markets.businessinsider.com logoVistaGen Therapeutics earnings: here's what Wall Street expects
markets.businessinsider.com - June 22 at 6:31 PM
finance.yahoo.com logoVistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
finance.yahoo.com - June 22 at 6:31 PM
finance.yahoo.com logoVistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
finance.yahoo.com - June 17 at 6:15 PM
marketwatch.com logoInvestorNewsBreaks - VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting
marketwatch.com - June 4 at 7:24 AM
finance.yahoo.com logoVistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
finance.yahoo.com - June 2 at 10:19 AM
finance.yahoo.com logoNurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
finance.yahoo.com - May 31 at 9:26 AM
finance.yahoo.com logoVistaGen to Participate in Upcoming June Investor Conferences
finance.yahoo.com - May 27 at 10:33 AM
finance.yahoo.com logoWhat You Need To Know About VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) Investor Composition
finance.yahoo.com - May 10 at 12:41 PM
seekingalpha.com logoVistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety
seekingalpha.com - May 5 at 3:06 PM
finance.yahoo.com logoVistaGen Appoints Reid Adler as Chief Legal Officer
finance.yahoo.com - May 2 at 8:42 AM
finance.yahoo.com logoVistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
finance.yahoo.com - April 21 at 10:48 AM
seekingalpha.com logoVistaGen, AffaMed plan to start global study of nasal spray PH94B for anxiety in H2
seekingalpha.com - April 12 at 1:22 PM
finance.yahoo.com logoGilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
finance.yahoo.com - April 12 at 1:22 PM
finance.yahoo.com logoVistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
finance.yahoo.com - April 12 at 8:22 AM
finance.yahoo.com logoNovartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
finance.yahoo.com - April 7 at 3:30 PM
finance.yahoo.com logoVistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
finance.yahoo.com - March 24 at 6:48 PM
finance.yahoo.com logoVistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
finance.yahoo.com - March 24 at 6:48 PM
finance.yahoo.com logoWe're Hopeful That VistaGen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely
finance.yahoo.com - March 19 at 10:27 AM
finance.yahoo.com logoVistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - February 10 at 6:34 PM
finance.yahoo.com logoVistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - February 10 at 6:34 PM
finance.yahoo.com logoVistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022
finance.yahoo.com - February 7 at 11:44 AM
finance.yahoo.com logoEarnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
finance.yahoo.com - February 3 at 6:16 PM
nasdaq.com logoVistaGen Therapeutics (NASDAQ:VTGN) Is In A Good Position To Deliver On Growth Plans
nasdaq.com - January 27 at 1:57 PM
nasdaq.com logoVistaGen Therapeutics Inc Shares Near 52-Week Low - Market Mover
nasdaq.com - January 21 at 10:37 AM
finance.yahoo.com logoShareholders in VistaGen Therapeutics (NASDAQ:VTGN) are in the red if they invested five years ago
finance.yahoo.com - January 18 at 3:47 PM
Get VistaGen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:VTGN) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.